Pemetrexed Injection, Powder, Lyophilized, For Solution
NDC Package 63323-621-00
Package Information
Pemetrexed (pemetrexed disodium) injection is pemetrexed is used to treat certain types of cancer (such as lung cancer, mesothelioma). This formulation utilizes a injection, powder, lyophilized, for solution delivery system. Marketed by Fresenius Kabi Usa, Llc, this product is identified by NDC 63323-621 and is authorized under FDA application ANDA090384.
Identification & Billing
- RxCUI: 1728072 - PEMEtrexed 500 MG Injection
- RxCUI: 1728072 - pemetrexed 500 MG Injection
- RxCUI: 1728077 - PEMEtrexed 100 MG Injection
- RxCUI: 1728077 - pemetrexed 100 MG Injection
- RxCUI: 2601728 - PEMEtrexed 1 GM Injection
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 63323 - Fresenius Kabi Usa, Llc
- 63323-621 - Pemetrexed
- 63323-621-00 - 1 VIAL, SINGLE-USE in 1 CARTON / 30 mL in 1 VIAL, SINGLE-USE
- 63323-621 - Pemetrexed
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 63323-621-00 identifies a specific commercial package of 1 vial, single-use in 1 carton / 30 ml in 1 vial, single-use of Pemetrexed, a human prescription drug labeled by Fresenius Kabi Usa, Llc. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This injection, powder, lyophilized, for solution is formulated for intravenous use and contains pemetrexed disodium as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Fresenius Kabi Usa, Llc on May 25, 2022. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Pemetrexed is used to treat certain types of cancer (such as lung cancer, mesothelioma). It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells.
How is this Fresenius Kabi Usa, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 63323062100. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.